- * Confirmed Crohn's Disease diagnosis via radiology, endoscopy or histology within prior 12 months. Diagnosed for at least 3 months
- * Active Disease with Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450
- * Failed conventional therapy or steroid dependent
Crohn's Disease
Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease
NCT01545050 | PHASE 2 | INTERVENTIONAL
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn's disease and who have had an insufficient response to conventional therapy or have failed Anti-Tumor Necrosis Factor (anti-TNF) therapy.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
University Of California, San Diego
La Jolla,California,United States,92093
Precision Research Institute, Llc
San Diego,California,United States,92114
South Denver Gastroenterology, Pc
Lone Tree,Colorado,United States,80124
University Of Florida
Gainesville,Florida,United States,32610
University Of Louisville
Louisville,Kentucky,United States,40202
Premier Medical Group Of The Hudson Valley, Pc
Poughkeepsie,New York,United States,12601
Options Health Research, Llc
Tulsa,Oklahoma,United States,74104
Gastro One
Germantown,Tennessee,United States,38138
Local Institution
Wien,Austria,1090
Local Institution
Calgary,Alberta,Canada,T2N4Z6
Local Institution
Vancouver,British Columbia,Canada,V6Z2K5
Local Institution
Saskatoon,Saskatchewan,Canada,S7N0W8
Local Institution
Hradec Kralove,Czechia,50012
Local Institution
Clermont-ferrand Cedex 1,France,63003
Local Institution
Lille Cedex,France,59037
Local Institution
Nice,France,06200
Local Institution
Pessac,France,33600
Local Institution
St Priest En Jarez,France,42270
Local Institution
Duesseldorf,Germany,40237
Local Institution
Frankfurt A. M,Germany,60431
Local Institution
Herne,Germany,44623
Local Institution
Kiel,Germany,24105
Local Institution
Magdeburg,Germany,39120
Local Institution
Muenster,Germany,48155
Local Institution
Hong Kong,Hong Kong
Local Institution
Budapest,Hungary,1136
Local Institution
Debrecen,Hungary,4025
Local Institution
Pecs,Hungary,7623
Local Institution
Hyderabad,Andhra Pradesh,India,500082
Local Institution
Mumbai,Maharashtra,India,400020
Local Institution
Ludhiana,India,141001
Local Institution
Mumbai,India,400029
Local Institution
Pune,India,411030
Local Institution
Jerusalem,Israel,91031
Local Institution
Rehovot,Israel,76100
Local Institution
Tel Aviv,Israel,64239
Local Institution
Firenze,Italy,50134
Local Institution
Padova,Italy,35128
Local Institution
Roma,Italy,00152
Local Institution
San Donato Milanese (mi),Italy,20097
Local Institution
San Giovanni Rotondo (fg),Italy,71013
Local Institution
Seoul,Korea, Republic of,120-752
Local Institution
Seoul,Korea, Republic of,135-710
Local Institution
Seoul,Korea, Republic of,138-736
Local Institution
Mexico,Distrito Federal,Mexico,14080
Local Institution
Monterrey,Nuevo Leon,Mexico,64460
Local Institution
Nijmegen,Netherlands,6500HB
Local Institution
Krakow,Poland,31-864
Local Institution
Lodz,Poland,90-302
Local Institution
Wroclaw,Poland,50-556
Local Institution
Wroclaw,Poland,53-114
Local Institution
Zuerich,Switzerland,8091
Local Institution
Kaohsiung,Taiwan,80756
Local Institution
Taipei,Taiwan,100
Local Institution
Hull,Kingston Upon Hull, City Of,United Kingdom,HU32JZ
Local Institution
Harrow,United Kingdom,HA12UJ
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov